Immune-related adverse events of biological immunotherapies used in COVID-19
Copyright © 2022 Baracaldo-Santamaría, Barros-Arias, Hernández-Guerrero, De-La-Torre and Calderon-Ospina..
The use of biological immunotherapeutic drugs is one of the options currently being evaluated and employed to manage COVID-19, specifically monoclonal antibodies, which have shown benefit by regulating the excessive immune response seen in patients with severe infection, known as a cytokine storm. Tocilizumab has received particular importance for this clinical application, as has sarilumab. Both drugs share a substantial similarity in terms of pharmacodynamics, being inhibitors of the interleukin six receptor (IL-6Rα). Furthermore, sotrovimab, a neutralizing anti-SARS CoV-2 antibody, has gained the attention of the scientific community since it has recently been authorized under certain circumstances, positioning itself as a new therapeutic alternative in development. However, despite their clinical benefit, biological immunotherapies have the potential to generate life-threatening immune-related adverse events. Therefore it is essential to review their incidence, mechanism, and risk factors. This review aims to provide a comprehensive understanding of the safety of the biological immunotherapeutic drugs currently recommended for the treatment of COVID-19, provide a review of the known immune-mediated adverse events and explore the potential immune-related mechanisms of other adverse reactions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 13(2022) vom: 07., Seite 973246 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baracaldo-Santamaría, Daniela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse reactions |
|---|
| Anmerkungen: |
Date Revised 13.09.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2022.973246 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346087732 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346087732 | ||
| 003 | DE-627 | ||
| 005 | 20231226030605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2022.973246 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346087732 | ||
| 035 | |a (NLM)36091800 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baracaldo-Santamaría, Daniela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune-related adverse events of biological immunotherapies used in COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Baracaldo-Santamaría, Barros-Arias, Hernández-Guerrero, De-La-Torre and Calderon-Ospina. | ||
| 520 | |a The use of biological immunotherapeutic drugs is one of the options currently being evaluated and employed to manage COVID-19, specifically monoclonal antibodies, which have shown benefit by regulating the excessive immune response seen in patients with severe infection, known as a cytokine storm. Tocilizumab has received particular importance for this clinical application, as has sarilumab. Both drugs share a substantial similarity in terms of pharmacodynamics, being inhibitors of the interleukin six receptor (IL-6Rα). Furthermore, sotrovimab, a neutralizing anti-SARS CoV-2 antibody, has gained the attention of the scientific community since it has recently been authorized under certain circumstances, positioning itself as a new therapeutic alternative in development. However, despite their clinical benefit, biological immunotherapies have the potential to generate life-threatening immune-related adverse events. Therefore it is essential to review their incidence, mechanism, and risk factors. This review aims to provide a comprehensive understanding of the safety of the biological immunotherapeutic drugs currently recommended for the treatment of COVID-19, provide a review of the known immune-mediated adverse events and explore the potential immune-related mechanisms of other adverse reactions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a adverse reactions | |
| 650 | 4 | |a monoclonal abs | |
| 650 | 4 | |a sarilumab | |
| 650 | 4 | |a siltuximab | |
| 650 | 4 | |a sotrovimab | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a Barros-Arias, Giovanna María |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Guerrero, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a De-La-Torre, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Calderon-Ospina, Carlos-Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 13(2022) vom: 07., Seite 973246 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:07 |g pages:973246 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2022.973246 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 07 |h 973246 | ||